<DOC>
	<DOC>NCT01522170</DOC>
	<brief_summary>There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.</brief_summary>
	<brief_title>aHUS Observational Long Term Follow-Up</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>aHUS patients who participated in any one of the aHUSeculizumab clinical studies. aHUS patients or legal representative who are able and willing to given written informed consent for their study information to be collected and retained in a database.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Atypical Hemolytic Uremic Syndrome</keyword>
	<keyword>aHUS</keyword>
	<keyword>Eculizumab</keyword>
</DOC>